MX2015005477A - Anticuerpos contra determinantes de la superficie de s. aureus. - Google Patents
Anticuerpos contra determinantes de la superficie de s. aureus.Info
- Publication number
- MX2015005477A MX2015005477A MX2015005477A MX2015005477A MX2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- aureus
- binding fragments
- chain variable
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen anticuerpos y fragmentos de unión al antígeno de estos dirigidos contra determinantes antigénicos de la superficie Staphylococcus aureus (S. aureus) y toxinas secretadas. También se proporcionan métodos para detectar, diagnosticar y tratar S. aureus empleando los anticuerpos y fragmentos de unión al antígeno de estos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723137P | 2012-11-06 | 2012-11-06 | |
US201361782405P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/068624 WO2014074540A2 (en) | 2012-11-06 | 2013-11-06 | Antibodies to s. aureus surface determinants |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015005477A true MX2015005477A (es) | 2015-11-30 |
Family
ID=50685304
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005477A MX2015005477A (es) | 2012-11-06 | 2013-11-06 | Anticuerpos contra determinantes de la superficie de s. aureus. |
MX2022008079A MX2022008079A (es) | 2012-11-06 | 2015-04-29 | Anticuerpos contra determinantes de la superficie de s. aureus. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008079A MX2022008079A (es) | 2012-11-06 | 2015-04-29 | Anticuerpos contra determinantes de la superficie de s. aureus. |
Country Status (17)
Country | Link |
---|---|
US (3) | US9879070B2 (es) |
EP (2) | EP2917360B1 (es) |
JP (2) | JP6694269B2 (es) |
KR (1) | KR102288394B1 (es) |
CN (2) | CN104968797B (es) |
AU (2) | AU2013341361A1 (es) |
BR (1) | BR112015010125A2 (es) |
CA (1) | CA2890427C (es) |
DK (1) | DK2917360T3 (es) |
ES (1) | ES2776179T3 (es) |
HK (2) | HK1215054A1 (es) |
HU (1) | HUE049012T2 (es) |
MX (2) | MX2015005477A (es) |
PL (1) | PL2917360T3 (es) |
RU (1) | RU2698131C2 (es) |
SG (2) | SG10201703678TA (es) |
WO (1) | WO2014074540A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2673373T1 (sl) * | 2011-02-08 | 2019-03-29 | Medimmune, Llc | Protitelesa, ki specifično vežejo alfa toksin Staphylococcus aureus in postopki uporabe |
MX349886B (es) | 2011-06-10 | 2017-08-17 | Medimmune Llc | Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas. |
HUE050985T2 (hu) * | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
CA2890385C (en) | 2012-11-06 | 2022-07-12 | Medimmune, Llc | Methods of treating s. aureus-associated diseases |
EP2917360B1 (en) * | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
CN106456763B (zh) * | 2014-06-03 | 2018-03-13 | 埃克斯生物科技公司 | 用于治疗和预防金黄色葡萄球菌感染的组合物和方法 |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
JP2017524943A (ja) * | 2014-08-12 | 2017-08-31 | アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | S.アウレウス疾患の予測 |
WO2016073860A1 (en) * | 2014-11-06 | 2016-05-12 | Medimmune, Llc | Binding molecules specific for staphylococcus protein a and uses thereof |
FR3033333A1 (fr) * | 2015-03-06 | 2016-09-09 | Commissariat Energie Atomique | Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations |
RU2017139800A (ru) * | 2015-04-17 | 2019-05-17 | Арсанис Байосайенсиз Гмбх | Комбинированный препарат антител против staphylococcus aureus |
US20190077851A1 (en) * | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
CN105424930A (zh) * | 2015-11-23 | 2016-03-23 | 天津科技大学 | 一种快速检测金黄色葡萄球菌的方法 |
SG11202001160XA (en) * | 2017-09-29 | 2020-03-30 | Regeneron Pharma | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
US11059884B2 (en) | 2018-10-09 | 2021-07-13 | Medimmune, Llc | Antibodies directed against Staphylococcus aureus leukotoxins |
AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
US20220127338A1 (en) | 2019-03-13 | 2022-04-28 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
KR102397684B1 (ko) * | 2019-12-09 | 2022-05-13 | (주)옵토레인 | 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법 |
KR102504175B1 (ko) * | 2020-06-17 | 2023-02-28 | (주)옵토레인 | 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법 |
JP2024501570A (ja) * | 2021-01-14 | 2024-01-12 | オプトレーン テクノロジーズ インコーポレイテッド | スイッチングペプチド及びそれを用いたマルチプレックス免疫分析方法 |
JP2024501571A (ja) * | 2021-01-14 | 2024-01-12 | オプトレーン テクノロジーズ インコーポレイテッド | スイッチングペプチド、それを含む免疫分析装置及びそれを用いた免疫分析方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2017198A (en) * | 1931-10-17 | 1935-10-15 | Anglada Motor Corp | Cuff valve engine |
US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
BR0207068A (pt) * | 2001-01-26 | 2004-12-21 | Inhibitex Inc | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus |
KR20060034231A (ko) | 2003-06-06 | 2006-04-21 | 메디뮨 인코포레이티드 | 암의 진단, 치료 및 예방에 있어서의 epha4 및epha4 조정제의 용도 |
US7348001B2 (en) | 2003-08-12 | 2008-03-25 | Dyax Corp. | Tie1-binding ligands |
WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
US20080050361A1 (en) | 2004-10-25 | 2008-02-28 | Heinrichs David E | Staphylococcus aureas specific anti-infectives |
JP2009528828A (ja) | 2006-03-06 | 2009-08-13 | シムフォゲン・アクティーゼルスカブ | 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体 |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
EP2043690A1 (en) * | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
WO2008152447A2 (en) * | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
US9526774B1 (en) * | 2006-11-06 | 2016-12-27 | Microvax, Llc | Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus |
US20110150918A1 (en) * | 2008-01-31 | 2011-06-23 | Timothy Foster | Treatment of microbial infections |
WO2009140236A2 (en) * | 2008-05-12 | 2009-11-19 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
WO2010005513A2 (en) * | 2008-06-30 | 2010-01-14 | The Texas A&M University System | Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
JP2012504660A (ja) * | 2008-10-06 | 2012-02-23 | ユニバーシティ オブ シカゴ | 細菌eap、empおよび/またはadsaタンパク質に関連する組成物および方法 |
WO2011019423A2 (en) * | 2009-05-20 | 2011-02-17 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
US8568735B2 (en) * | 2009-06-22 | 2013-10-29 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
EA031447B1 (ru) * | 2009-07-15 | 2019-01-31 | Аимм Терапьютикс Б.В. | Антитела, которые связываются с sdr белками, и способы их использования |
GB0913680D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
EP2516467A2 (en) * | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
JP2013523818A (ja) * | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | 免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法 |
JP5793194B2 (ja) * | 2010-09-09 | 2015-10-14 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 感染防御ブドウ球菌抗原が関与する方法および組成物 |
US20120202047A1 (en) | 2011-02-07 | 2012-08-09 | Baker Hughes Incorporated | Nano-coatings for articles |
SI2673373T1 (sl) * | 2011-02-08 | 2019-03-29 | Medimmune, Llc | Protitelesa, ki specifično vežejo alfa toksin Staphylococcus aureus in postopki uporabe |
CN103906535B (zh) * | 2011-08-15 | 2017-07-14 | 芝加哥大学 | 与葡萄球菌蛋白a的抗体相关的组合物和方法 |
CA2859667C (en) * | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
EP3805395A1 (en) * | 2012-04-26 | 2021-04-14 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
CA2890385C (en) * | 2012-11-06 | 2022-07-12 | Medimmune, Llc | Methods of treating s. aureus-associated diseases |
EP2917360B1 (en) * | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
CN104994875B (zh) * | 2013-02-15 | 2018-10-09 | 免疫医疗公司 | 嵌合和人源化抗组蛋白抗体 |
US20160235832A1 (en) * | 2013-10-15 | 2016-08-18 | The Texas A&M University System | Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery |
US20170023569A1 (en) * | 2014-01-10 | 2017-01-26 | University Of Rochester | Diagnostic device and method for detection of staphylococcus infection |
AU2015209140B2 (en) * | 2014-01-24 | 2020-01-02 | William R. Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
CN106456763B (zh) * | 2014-06-03 | 2018-03-13 | 埃克斯生物科技公司 | 用于治疗和预防金黄色葡萄球菌感染的组合物和方法 |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
WO2016073860A1 (en) * | 2014-11-06 | 2016-05-12 | Medimmune, Llc | Binding molecules specific for staphylococcus protein a and uses thereof |
RU2017139800A (ru) | 2015-04-17 | 2019-05-17 | Арсанис Байосайенсиз Гмбх | Комбинированный препарат антител против staphylococcus aureus |
US20190077851A1 (en) * | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
US11344615B2 (en) * | 2016-07-08 | 2022-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells |
BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
AU2019357983A1 (en) * | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
US11059884B2 (en) * | 2018-10-09 | 2021-07-13 | Medimmune, Llc | Antibodies directed against Staphylococcus aureus leukotoxins |
US20220127338A1 (en) * | 2019-03-13 | 2022-04-28 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
-
2013
- 2013-11-06 EP EP13852597.7A patent/EP2917360B1/en active Active
- 2013-11-06 HU HUE13852597A patent/HUE049012T2/hu unknown
- 2013-11-06 BR BR112015010125A patent/BR112015010125A2/pt not_active Application Discontinuation
- 2013-11-06 SG SG10201703678TA patent/SG10201703678TA/en unknown
- 2013-11-06 AU AU2013341361A patent/AU2013341361A1/en not_active Abandoned
- 2013-11-06 RU RU2015121624A patent/RU2698131C2/ru active
- 2013-11-06 EP EP19211610.1A patent/EP3640338A1/en active Pending
- 2013-11-06 SG SG11201503232TA patent/SG11201503232TA/en unknown
- 2013-11-06 JP JP2015540879A patent/JP6694269B2/ja active Active
- 2013-11-06 DK DK13852597.7T patent/DK2917360T3/da active
- 2013-11-06 CN CN201380057603.9A patent/CN104968797B/zh active Active
- 2013-11-06 WO PCT/US2013/068624 patent/WO2014074540A2/en active Application Filing
- 2013-11-06 PL PL13852597T patent/PL2917360T3/pl unknown
- 2013-11-06 CA CA2890427A patent/CA2890427C/en active Active
- 2013-11-06 US US14/440,748 patent/US9879070B2/en active Active
- 2013-11-06 MX MX2015005477A patent/MX2015005477A/es active IP Right Grant
- 2013-11-06 CN CN201811621407.0A patent/CN109553681A/zh active Pending
- 2013-11-06 ES ES13852597T patent/ES2776179T3/es active Active
- 2013-11-06 KR KR1020157014912A patent/KR102288394B1/ko active IP Right Grant
-
2015
- 2015-04-29 MX MX2022008079A patent/MX2022008079A/es unknown
-
2016
- 2016-03-15 HK HK16102947.2A patent/HK1215054A1/zh unknown
- 2016-03-22 HK HK16103336.9A patent/HK1215452A1/zh unknown
-
2018
- 2018-01-25 US US15/880,157 patent/US10730934B2/en active Active
- 2018-10-04 AU AU2018241107A patent/AU2018241107B2/en active Active
-
2019
- 2019-01-25 JP JP2019011283A patent/JP2019089801A/ja not_active Withdrawn
-
2020
- 2020-07-09 US US16/925,129 patent/US11447543B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008079A (es) | Anticuerpos contra determinantes de la superficie de s. aureus. | |
PH12016501384B1 (en) | Human antibodies to pd-l1 | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
PH12017500890A1 (en) | Antibody drug conjugates | |
MX2017016253A (es) | Anticuerpos para cd40. | |
NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
NZ629296A (en) | Humanized antibodies that recognize alpha-synuclein | |
MX356947B (es) | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
WO2015054691A8 (en) | Tem8 antibodies and their use | |
WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
TR201817932T4 (tr) | Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇ | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
WO2012135740A3 (en) | Cd37-binding molecules and immunoconjugates thereof | |
DK2681244T3 (da) | Cea-antistoffer | |
MX2015005719A (es) | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
WO2014200898A3 (en) | Cmv neutralizing antigen binding proteins | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
MY191739A (en) | Antibodies specific for enteroviruses that infect humans | |
WO2014062659A3 (en) | Methods of treating ocular diseases | |
MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |